G-CSF/GM-CSF-induced hematopoietic dysregulation in the progression of solid tumors

FEBS Open Bio. 2022 Jul;12(7):1268-1285. doi: 10.1002/2211-5463.13445. Epub 2022 Jun 9.

Abstract

There are two types of abnormal hematopoiesis in solid tumor occurrence and treatment: pathological hematopoiesis, and myelosuppression induced by radiotherapy and chemotherapy. In this review we primarily focus on the abnormal pathological hematopoietic differentiation in cancer induced by tumor-released granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). As key factors in hematopoietic development, G-CSF/GM-CSF are well-known facilitators of myelopoiesis and mobilization of hematopoietic stem cells (HSCs). In addition, these two cytokines can also promote or inhibit tumors, dependent on tumor type. In multiple cancer types, hematopoiesis is greatly enhanced and abnormal lineage differentiation is induced by these two cytokines. Here, dysregulated hematopoiesis induced by G-CSF/GM-CSF in solid tumors and its mechanism are summarized, and the prognostic value of G-CSF/GM-CSF-associated dysregulated hematopoiesis for tumor metastasis is also briefly highlighted.

Keywords: granulocyte colony-stimulating factor; granulocyte-macrophage colony-stimulating factor; hematopoiesis; metastasis; prognostic; solid tumor.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines
  • Granulocyte Colony-Stimulating Factor / metabolism
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Granulocyte-Macrophage Colony-Stimulating Factor* / metabolism
  • Granulocyte-Macrophage Colony-Stimulating Factor* / pharmacology
  • Granulocyte-Macrophage Colony-Stimulating Factor* / therapeutic use
  • Hematopoiesis
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Cytokines
  • Granulocyte Colony-Stimulating Factor
  • Granulocyte-Macrophage Colony-Stimulating Factor